NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
15.43
+0.38 (2.52%)
At close: Jun 26, 2026, 4:00 PM EDT
15.40
-0.03 (-0.19%)
After-hours: Jun 26, 2026, 5:59 PM EDT

Company Description

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally.

Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.

NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

NovoCure Limited
NovoCure logo
Country Switzerland
Founded 2000
IPO Date Oct 2, 2015
Industry Medical Devices
Sector Healthcare
Employees 1,605
CEO Frank Leonard

Contact Details

Address:
Neuhofstrasse 21
Baar, 6340
Switzerland
Website novocure.com

Stock Details

Ticker Symbol NVCR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001645113
CUSIP Number G6674U108
ISIN Number JE00BYSS4X48
SIC Code 3841

Key Executives

Name Position
Frank Leonard Chief Executive Officer and Director
William F. Doyle Executive Chairman
Christoph Brackmann Chief Financial Officer
Michael Puri Chief Human Resources Officer
Dr. Uri Weinberg M.D., Ph.D. Chief Innovation Officer and Chief Medical Officer
Mukund Paravasthu Chief Operating Officer
Adam Daney Head of Investor Relations
Barak Ben-Arye General Counsel

Latest SEC Filings

Date Type Title
Jun 18, 2026 8-K Current Report
Jun 5, 2026 8-K Current Report
Jun 4, 2026 144 Filing
May 21, 2026 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 8, 2026 SCHEDULE 13G/A Filing
Apr 30, 2026 8-K Current Report
Apr 30, 2026 10-Q Quarterly Report
Apr 28, 2026 SCHEDULE 13G Filing
Apr 24, 2026 8-K/A [Amend] Current report
Apr 20, 2026 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material